What amount sold does Model Medicines, Inc. report in Form D filings?

The latest linked filings report $27.6M sold across 5 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Model Medicines, Inc.'s most recent SEC filing?

Model Medicines, Inc.'s most recent Form D filing was on 2026-10-21.

How many investors does Model Medicines, Inc. have?

The most recent Form D filing lists 37 investor(s).

What type of securities does Model Medicines, Inc. offer?

Model Medicines, Inc.'s SEC Form D filings indicate equity offerings.

Model Medicines, Inc.

CIK: 0001892786·Other·SAN DIEGO, CA·Corporation

Reported Sold

$27,579,300

Total Filings

Identified Offerings

Last Filed

Oct 21, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Other industry

SEC EDGAR

Offering filing timeline

Oct 21, 2026Form D — New notice

Reported sold: $5,115,268 · Target: $8,000,000

Rule 506(b)·37 investors

Nov 14, 2025Form D — New notice

Reported sold: $3,260,000 · Target: $5,000,000

Rule 506(b)·10 investors

Oct 15, 2024Form D — New notice

Reported sold: $14,754,032 · Target: Indefinite

Rule 506(b)·43 investors

Feb 7, 2024Form D — New notice

Reported sold: $950,000 · Target: $2,000,000

Rule 506(b)·10 investors

Nov 9, 2021Form D — New notice

Reported sold: $3,500,000 · Target: $3,500,000

Rule 506(b)·5 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 5 identified offerings

$27,579,300

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Daniel Haders

Executive Officer, Director

Appears on 3 filings

Marlon Evans

Executive Officer, Director

Appears on 3 filings

Kip Quackenbush

Executive Officer, Director

Appears on 3 filings

Daniel Haders

Related Person

Appears on 1 filing

Daniel Haders

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 21, 2026	New	$8,000,000	$5,115,268	37
Nov 14, 2025	New	$5,000,000	$3,260,000	10
Oct 15, 2024	New	Indefinite	$14,754,032	43
Feb 7, 2024	New	$2,000,000	$950,000	10
Nov 9, 2021	New	$3,500,000	$3,500,000	5

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Agilis Medical, Inc.

Other

Offering target: $10,000,000

Filed Oct 28, 2026